Evidence map›Paper›PMID 27602113›Full record

ArticleOncology letters2016

Effect of MUC1/β-catenin interaction on the tumorigenic capacity of pancreatic CD133

Andreia Mota Sousa, Margarida Rei, Rita Freitas, Sara Ricardo, Thomas Caffrey, Leonor David, Raquel Almeida, Michael Anthony Hollingsworth, Filipe Santos-Silva

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Association between MUC1 rs4072037 polymorphism andCaspian journal of internal medicine · 2024
    Article
  9. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Andreia Mota SousaInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal.
Margarida ReiInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal.
Rita FreitasInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal.
Sara RicardoInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal; Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal.
Thomas CaffreyEppley Institute for Research in Cancer and Allied Disease, University of Nebraska Medical Center, Omaha, NE 68198-5950, USA.
Leonor DavidInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal; Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal.
Raquel AlmeidaInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal; Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal; Faculty of Sciences of the University of Porto, Porto 4169-007, Portugal.
Michael Anthony HollingsworthEppley Institute for Research in Cancer and Allied Disease, University of Nebraska Medical Center, Omaha, NE 68198-5950, USA.
Filipe Santos-SilvaInstitute of Research and Innovation in Health, University of Porto, Porto 4200-135, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal; Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal.
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the fact that the biological function of cluster of differentiation (CD)133 remains unclear, this glycoprotein is currently used in the identification and isolation of tumor-initiating cells from certain malignant tumors, including pancreatic cancer. In the present study, the involvement of mucin 1 (MUC1) in the signaling pathways of a highly tumorigenic CD133+ cellular subpopulation sorted from the pancreatic cancer cell line HPAF-II was evaluated. The expression of MUC1-cytoplasmic domain (MUC1-CD) and oncogenic signaling transducers (epidermal growth factor receptor, protein kinase C delta, glycogen synthase kinase 3 beta and growth factor receptor-bound protein 2), as well as the association between MUC1 and β-catenin, were characterized in HPAF-II CD133+ and CD133low cell subpopulations and in tumor xenografts generated from these cells. Compared with HPAF CD133

Indexed as

cancer stem cellscell signalingMUC1pancreatic cancer

Identifiers

PMID27602113
PMCPMC4998183
OpenAlexW2499477582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.